ZEB2 and familial pancreatic carcinoma: Specifically, ZEB1 was found to be significantly associated with poor OS for pancreatic cancer, gastric cancer and colorectal cancer patients, while ZEB2 was found to be significantly associated with poor OS for hepatocellular carcinoma and gastric cancer patients.